ReviewBritish journal of clinical pharmacology2020
New psychoactive substances: Pharmacology influencing UK practice, policy and the law.
Review in British journal of clinical pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 19 citations in OpenAlex.
- Novel Synthetic Opioids (NSOs) and Their Evolving Crisis: Utilising NPSPharmaceuticals (Basel, Switzerland) · 2025Article
- MDMA-assisted therapy: challenges, clinical trials, and the future of MDMA in treating behavioral disorders.CNS spectrums · 2025Review
- Legislating novel psychoactive substances: lessons from 15 years of UK mortality data (2007-2022).Frontiers in pharmacology · 2025Article
- Club Drugs and Psychiatric Outcomes: A Descriptive Case Series from Spain.Pharmaceuticals (Basel, Switzerland) · 2024Article
- A review of synthetic cathinones emerging in recent years (2019-2022).Forensic toxicology · 2023Review
- Deaths from novel psychoactive substances in England, Wales and Northern Ireland: Evaluating the impact of the UK psychoactive substances act 2016.Journal of psychopharmacology (Oxford, England) · 2021Article
- New psychoactive substances: Pharmacology influencing UK practice, policy and the law.British journal of clinical pharmacology · 2020Review
- The challenge of the novel psychoactive substances: How have we responded and what are the implications of this response?British journal of clinical pharmacology · 2020Article
- New psychoactive substances: a review and updates.Therapeutic advances in psychopharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review covers the last 20 years of UK drug control policy leading up to the recent Psychoactive Substances Act. It explores policy decision made in relation to MDMA and mephedrone that not only were associated with increased drug harms overall but also had a significant detrimental effect on the UK research base. The new UK legislation on synthetic cannabinoids and other novel psychoactive substances threatens to do the same, showing that there is still much to learn from the decisions of the past. In future input from academic societies such as the BPS could help improve policy evaluation and policy development and so help avoid such problems in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.